Toggle light / dark theme

Billionaire Jim Mellon invests in anti-ageing research firm

Billionaire investor Jim Mellon has joined the push to solve age-related diseases and bring rejuvenation biotechnology to the world.


Billionaire biotechnology investor Jim Mellon has unveiled an investment in an ambitious new venture which seeks to tackle ageing and age-related diseases.

Insilico Medicine is a big data analytics company which says its mission is to ‘extend healthy longevity’.

This is a ‘moonshot’ target in health which has seen investment from a number of ambitious research groups in the last few years.

Liz Parrish — Human of the Future

New one from Liz.


Full Video ► https://goo.gl/tHvTF5
BioViva ► http://bioviva-science.com

Liz Parrish is the Founder and CEO of BioViva Sciences USA Inc. BioViva is committed to extending healthy lifespans using gene therapy. Liz is known as “the woman who wants to genetically engineer you,” she is a humanitarian, entrepreneur and innovator and a leading voice for genetic cures. As a strong proponent of progress and education for the advancement of gene therapy, she serves as a motivational speaker to the public at large for the life sciences. She is actively involved in international educational media outreach and sits on the board of the International Longevity Alliance (ILA). She is the founder of BioTrove Investments LLC and the BioTrove Podcasts which is committed to offering a meaningful way for people to learn about and fund research in regenerative medicine. She is also the Secretary of the American Longevity Alliance (ALA) a 501©(3) nonprofit trade association that brings together individuals, companies, and organizations who work in advancing the emerging field of cellular & regenerative medicine with the aim to get governments to consider aging a disease.

Parrish received two kinds of injections, which were administered outside the United States: a myostatin inhibitor, which is expected to prevent age-associated muscle loss; and a telomerase gene therapy, which is expected to lengthen telomeres, segments of DNA at the ends of chromosomes whose shortening is associated with aging and degenerative disease.

——-

Reprogramming brain cells offers hope for Parkinson’s

This week saw researchers announce a promising new approach to Parkinson’s by the use of cellular reprogramming. The team lead by Ernest Arenas used a cocktail of four transcription factors to reprogram support cells inside the brain.

The research team placed the reprogramming factors into a harmless type of lentivirus and injected them en masse into a Parkinson’s disease model mice. The viruses infected support cells in the brain known as astrocytes (a support cell that regulates the transmission of electrical impulses within the brain) which are present in large numbers. The lentiviruses delivered their four factor payload to the target cells changing them from astrocytes into dopamine producing neurons.

Within three weeks the first cells had been reprogrammed and could be detected, and after fifteen weeks there were abundant numbers of dopamine producing neurons present. This is good news indeed as it also confirms that once reprogrammed the cells remain changed and stable and do not revert back into astrocytes.

Billionaire investor to accelerate research in artificial intelligence in healthcare

Interest in rejuvenation biotechnology is growing rapidly and attracting investors.


- Jim Mellon has made an investment in Insilico Medicine to enable the company to validate the many molecules discovered using deep learning and launch multi-modal biomarkers of human aging

Monday, April 10, 2017, Baltimore, MD — Insilico Medicine, Inc, a big data analytics company applying deep learning techniques to drug discovery, biomarker development, and aging research today announced that it has closed an investment from the billionaire biotechnology investor Jim Mellon. Proceeds will be used to perform pre-clinical validation of multiple lead molecules developed using Insilico Medicine’s drug discovery pipelines and to advance research in deep learned biomarkers of aging and disease.

“Unlike many wealthy business people who rely entirely on their advisors to support their investment in biotechnology, Jim Mellon has spent a substantial amount of time familiarizing himself with recent developments in biogerontology. He does not just come in with the funding, but brings in expert knowledge and a network of biotechnology and pharmaceutical executives, who work very quickly and focus on the commercialization potential. We are thrilled to have Mr. Mellon as one of our investors and business partners”, said Alex Zhavoronkov, PhD, founder, and CEO of Insilico Medicine, Inc.

New drug aimed at slowing aging heads to the clinic

Everolimus heading for human clinical trials later this year to treat immune system decline.


The biotechnology company PureTech are moving towards human clinical trials with a new therapy that may slow down the aging process and combat age-related disease. The company has licensed two new drug candidates, derivatives of the drug Rapamycin, from pharmaceutical giant Novartis.

PureTech have recently announced a joint venture with Novartis called resTORbio and are moving to clinical trials of the new drugs later this year. The aim of the first test phase is to see if the new drug can rejuvenate the immune system of aged people a key reason why we lose the ability to resist diseases as we grow older.

Novartis already successfully completed two Phase IIa studies exploring the immune-enhancing potential of mTORC1 inhibitors in elderly patients. resTORbio plans to build on those findings and start a Phase IIb study with the two licensed candidates later this year. Excitingly the firm has also said that it plans to extend the program to other age-related disorders in the future.

Innovation in the Bay Area: Q&A with Nidhi Kalra

For people in that area, and it may be worth while to try reaching out to them for funding for anti aging stuff.


Why is RAND opening a Bay Area office?

The San Francisco Bay Area is really at the center of technology and transformation. That’s also been a focus at RAND since our very first report, Preliminary Design of an Experimental World-Circling Spaceship, in 1946, which foretold the creation of satellites more than a decade before Sputnik.

Today, our researchers are working on important questions related to autonomous vehicles, drones, cybersecurity, education technology, virtual medicine—the same questions driving Silicon Valley startups and billion-dollar Bay Area corporations. At the same time, we’re looking at issues surrounding social inequality, drug policy, water resource management, and transportation, all of which directly relate to the Bay Area.

These Species Can Recode Their Own Genetics

Technically, an animal could use RNA editing to change the nature of its proteins without completely altering the underlying DNA instructions. This makes the cephalopods’ ability to do it a very interesting phenomenon, but it’s unclear as to why the species requires this much RNA editing. Many of the edited proteins were found in the animals’ brains, which is why scientists think the editing and their brainpower could be linked.


More than any other species on earth, octopuses are particularly smart—they can solve puzzles, use tools, and communicate using color. Now scientists are saying they’re also capable of editing their RNA.

A team of scientists led by Joshua Rosenthal at the Marine Biological Laboratory and Noa Liscovitch-Braur and Eli Eisenberg at Tel Aviv University have discovered that octopuses and squid are capable of a type of genetic alteration called RNA editing. The process is rare among other species, leading scientists to believe that the cephalopods have evolved to follow a special kind of gene recoding.

Normally, living creatures use the information contained in DNA to make proteins, and RNA is the go-between, simply transmitting the message in the DNA. More than 60 percent of RNA transcripts in squid are recoded by editing, and similar levels of RNA editing were identified in other cephalopod species, including two octopuses and a cuttlefish. This changes the message that gets sent out, which in turn changes the proteins that get produced. In comparison, other species like fruit flies and humans experience recoding events only a fraction of one percent of the time. But exactly how the gene editing mechanics work is a mystery.

/* */